Home/Arsenal Biosciences/Ken Drazan, MD
KD

Ken Drazan, MD

Chairman, CEO, Co-Founder

Arsenal Biosciences

Roles

Chairman, CEO, Co-FounderatArsenal Biosciences

Therapeutic Areas

Arsenal Biosciences Pipeline

DrugIndicationPhase
AB-3028Metastatic Castration-Resistant Prostate Cancer (mCRPC)IND-Enabling
AB-7000Undisclosed Solid TumorIND-Enabling
AB-4000 Series (with BMS)Solid TumorsDiscovery/Preclinical